呼吸道合胞病毒（RSV）和3型副流感病毒（PIV3）疫苗研发的现状：世界卫生组织/美国国立过敏和传染病研究所联合会议纪要
Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
作者信息
Murphy B R, Collins P L
机构信息
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases NIH, Bethesda, MD, USA.
出版信息
Bull World Health Organ. 1997;75(4):307-13.
A Joint WHO/National Institute of Allergy and Infectious Diseases (NIAID) meeting on the current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development was held in Bethesda, MD, from 30 September to 1 October 1996. The meeting summarized the worldwide impact of RSV and PIV3; presented the current status of development of RSV and PIV3 vaccines; and examined the applications of recombinant DNA technology to the development and characterization of vaccines and to the understanding of viral pathogenesis.
1996年9月30日至10月1日，世界卫生组织（WHO）与美国国立过敏和传染病研究所（NIAID）就呼吸道合胞病毒（RSV）和3型副流感病毒（PIV3）疫苗研发的现状举行了一次联合会议。会议总结了RSV和PIV3在全球范围内的影响；介绍了RSV和PIV3疫苗的研发现状；并探讨了重组DNA技术在疫苗研发与特性分析以及理解病毒发病机制方面的应用。
Zotero 插件